NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1097-1103

  Ishikawa, Masako ^a   Nakayama, Kentaro ^a   Yeasmin, Shamima ^a   Katagiri, Atsuko ^a   Iida, Kouji ^a   Nakayama, Naomi ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Endometrial cancer; NAC1; Normal endometrium; Ovarian sex steroid

Indexed keywords

CELL PROTEIN; PROTEIN NAC1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BODY MASS INDEX; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; REPRESSOR PROTEINS;

EID: 77950440637     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000591     Document Type: Article

References (34)

1. Pisani P, Bray F and Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81, 2002.
2. Shiozawa T and Konishi I: Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol 11: 13-21, 2006.
3. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P and Prat J: Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32: 569-577, 2001.
4. Lax SF: Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444: 213-223, 2004.
5. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940, 1997.
6. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR and Hedrick L: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150: 177-185, 1997.
7. Levy C, Robel P, Gautray JP, De Brux J, Verma U, Descomps B and Baulieu EE: Estradiol and progesterone receptors in human endometrium: normal and abnormal menstrual cycles and early pregnancy. Am J Obstet Gynecol 136: 646-651, 1980.
8. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL and McCarty KS Jr: Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67: 334-340, 1988.
9. Giudice LC: Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 61: 1-17, 1994.
10. Stogios PJ, Downs GS, Jauhal JJ, Nandra SK and Prive GG: Sequence and structural analysis of BTB domain proteins. Genome Biol 6: R82, 2005.
11. Bardwell VJ and Treisman R: The POZ domain: a conserved protein-protein interaction motif. Genes Dev 8: 1664-1677, 1994.
12. Albagli O, Dhordain P, Deweindt C, Lecocq G and Leprince D: The BTB/POZ domain: a new protein-protein interaction motif common to DNA- and actin-binding proteins. Cell Growth Differ 6: 1193-1198, 1995.
13. David G, Alland L, Hong SH, Wong CW, De Pinho RA and Dejean A: Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16: 2549-2556, 1998.
14. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, Kerckaert JP, Evans RM and Leprince D: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci USA 94: 10762-10767, 1997.
15. Huynh KD and Bardwell VJ: The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17: 2473-2484, 1998.
16. Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG and Licht JD: Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 22: 1804-1818, 2002.
17. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL and Shih IeM: A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 103: 18739-18744, 2006.
18. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW and Orkin SH: A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368, 2006.
19. Davidson B, Berner A, Trope CG, Wang TL and Shih IeM: Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 38: 1030-1036, 2007.
20. Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N and Miyazaki K: Expression of the Bric-a-Brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 14: 1686-1691, 2008.
21. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M and Miyazaki K: A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 14: 3149-3155, 2008.
22. Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N and Miyazaki K: Expression of a BTB/POZ protein, NAC1, is essential for the proliferation of normal cyclic endometrial glandular cells and is up-regulated by estrogen. Clin Cancer Res 15: 804-811, 2009.
23. Noyes RW, Hertig AT and Rock J: Dating the endometrial biopsy. Am J Obstet Gynecol 122: 262-263, 1975.
24. Mao TL, Seidman JD, Kurman RJ and Shih IeM: Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor - an aid in differential diagnosis. Am J Surg Pathol 30: 1105-1110, 2006.
25. Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M and Takebayashi Y: Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8: 1285-1287, 2001.
26. Sutton G: Hormonal aspects of endometrial cancer. Curr Opin Obstet Gynecol 2: 69-73, 1990.
27. Kurman RJ, Kaminski PF and Norris HJ: The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 56: 403-412, 1985.
28. Uchikawa J, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Oka K and Konishi I: Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 98: 2207-2213, 2003.
29. Takai N, Miyazaki T, Nishida M, Shang S, Nasu K and Miyakawa I: Clinical relevance of Elf-1 overexpression in endometrial carcinoma. Gynecol Oncol 89: 408-413, 2003.
30. Sorosky JI: Endometrial cancer. Obstet Gynecol 111: 436-447, 2008.
31. Uharcek P: Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 34: 776-783, 2008.
32. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S and Dahiya R: Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res 61: 3262-3266, 2001.
33. Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB and Auersperg N: Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Clin Cancer Res 10: 7958-7964, 2004.
34. Kim J, Chu J, Shen X, Wang J and Orkin SH: An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132: 1049-1061, 2008.